Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference

(TheNewswire)

London, Ontario – TheNewswire - September 8 , 2025 - Sernova Biotherapeutics (“Sernova”) (TSX: SVA)(OTCQB: SEOVF) (FSE/XETRA: PSH) a leading regenerative medicinecompany focused on developing its Cell Pouch Bio-hybrid Organ as afunctional cure for type 1 diabetes (T1D), todayannounced it will be participating in the upcoming H.C. Wainwright27th Annual Global Investment Conference being held September 8-10,2025.

Jonathan Rigby, Sernova’s President and CEO, willprovide a company overview in a virtualpresentation and will be participating in virtual one-on-one investormeetings. Please contact your representative at H.C. Wainwright toschedule a meeting with the management team during theconference.

ABOUT SERNOVA BIOTHERAPEUTICS

Sernova Biotherapeutics is a clinical-stage companydeveloping regenerative medicine therapeutics combining its Cell Pouchwith human donor cells or stem-cell derived islet-like clusters incollaboration with Evotec to create bio-hybrid organs to treat T1D. Abio-hybrid organ is comprised of non-biomaterials, such as the CellPouch, integrated with living tissues to restore or enhance thefunction of a compromised organ. This innovative approach aims todeliver a potentially revolutionary treatment for patients withchronic diseases, initially focusing on T1D and thyroiddisorders.

FOR FURTHER INFORMATION, PLEASECONTACT:

David Burke VP, Investor Relations (917) 751-5713

Email: David.Burke@sernova.com

Website: https://sernova.com/

The TSX has not reviewed this news release and does notaccept responsibility for the accuracy or adequacy of this newsrelease.

Copyright (c) 2025 TheNewswire - All rights reserved.